267 related articles for article (PubMed ID: 27395403)
1. Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis.
Bernagie C; Danckaerts M; Wampers M; De Hert M
CNS Drugs; 2016 Sep; 30(9):807-18. PubMed ID: 27395403
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Aripiprazole alone or in combination for acute mania.
Brown R; Taylor MJ; Geddes J
Cochrane Database Syst Rev; 2013 Dec; (12):CD005000. PubMed ID: 24346956
[TBL] [Abstract][Full Text] [Related]
4. Risk of Extrapyramidal Adverse Events With Aripiprazole.
Etminan M; Procyshyn RM; Samii A; Carleton BC
J Clin Psychopharmacol; 2016 Oct; 36(5):472-4. PubMed ID: 27580493
[TBL] [Abstract][Full Text] [Related]
5. Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
Carbon M; Kapoor S; Sheridan E; Al-Jadiri A; Azzo S; Sarkaria T; Kane JM; Saito E; Correll CU
J Am Acad Child Adolesc Psychiatry; 2015 Sep; 54(9):718-727.e3. PubMed ID: 26299293
[TBL] [Abstract][Full Text] [Related]
6. Sertindole for schizophrenia.
Lewis R; Bagnall AM; Leitner M
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD001715. PubMed ID: 16034864
[TBL] [Abstract][Full Text] [Related]
7. Safety of aripiprazole for tics in children and adolescents: A systematic review and meta-analysis.
Yang C; Yi Q; Zhang L; Cui H; Mao J
Medicine (Baltimore); 2019 May; 98(22):e15816. PubMed ID: 31145316
[TBL] [Abstract][Full Text] [Related]
8. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia.
Muscettola G; Barbato G; Pampallona S; Casiello M; Bollini P
J Clin Psychopharmacol; 1999 Jun; 19(3):203-8. PubMed ID: 10350026
[TBL] [Abstract][Full Text] [Related]
9. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.
Gentile S
J Clin Psychopharmacol; 2007 Feb; 27(1):35-45. PubMed ID: 17224710
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
12. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation.
Satterthwaite TD; Wolf DH; Rosenheck RA; Gur RE; Caroff SN
J Clin Psychiatry; 2008 Dec; 69(12):1869-79. PubMed ID: 19192477
[TBL] [Abstract][Full Text] [Related]
14. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.
Preskorn SH; Macaluso M
J Psychiatr Pract; 2016 Mar; 22(2):117-23. PubMed ID: 27138080
[TBL] [Abstract][Full Text] [Related]
15. Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.
J Clin Psychiatry; 1998; 59 Suppl 12():23-7. PubMed ID: 9766616
[TBL] [Abstract][Full Text] [Related]
16. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).
Ostinelli EG; Jajawi S; Spyridi S; Sayal K; Jayaram MB
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD008074. PubMed ID: 29308601
[TBL] [Abstract][Full Text] [Related]
18. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
Maher AR; Theodore G
J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.
Gao K; Kemp DE; Ganocy SJ; Gajwani P; Xia G; Calabrese JR
J Clin Psychopharmacol; 2008 Apr; 28(2):203-9. PubMed ID: 18344731
[TBL] [Abstract][Full Text] [Related]
20. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
Moteshafi H; Zhornitsky S; Brunelle S; Stip E
Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
